Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04452292 · ClinicalTrials.gov registry record · NA
Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma
A NA study of Large Cell Neuroendocrine Carcinoma, sponsored by Charles Kunos.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT04452292: Completed NA study of Large Cell Neuroendocrine Carcinoma, sponsored by Charles Kunos.
NCT04452292 is a NA study of Large Cell Neuroendocrine Carcinoma that has completed, run by Charles Kunos. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04452292, a NA study of Large Cell Neuroendocrine Carcinoma, has completed, sponsored by Charles Kunos.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
PRECISION-NEC is a single-center, open-label, pilot feasibility study of molecularly defined subtypes of metastatic high-grade neuroendocrine carcinoma (HG-NEC). The hypothesis is that HG-NEC (excluding small cell carcinoma) can be segregated based on mutational analysis and that next generation sequencing (NGS)-based assignment of therapy is feasible and will potentially improve the outcomes.
Primary Outcome
Percentage of patients able to be sequenced within 2 months of the initial medical oncology visit.
Conditions Studied
Interventions
- OTHER Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma
- OTHER Treatment for Small Cell Lung Cancer
Study Locations (1)
Kentucky
- Markey Cancer Center, University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2023-03-14 |
| Phase | NA |
What the finished NCT04452292 record still lists
NCT04452292 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Large Cell Neuroendocrine Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma is the first listed.
NCT04452292 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT04452292 about?
NCT04452292 is a clinical study titled "Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma". PRECISION-NEC is a single-center, open-label, pilot feasibility study of molecularly defined subtypes of metastatic high-grade neuroendocrine carcinoma (HG-NEC). The hypothesis is that HG-NEC (excluding small cell carcinoma) can be segregated based on mutational analysis and that next generation seq...
What is the current status of trial NCT04452292?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2021-09-14. Estimated completion is 2023-03-14.
What conditions does trial NCT04452292 study?
This clinical trial studies the following conditions: Large Cell Neuroendocrine Carcinoma.
What interventions are being tested in trial NCT04452292?
The interventions under investigation include: Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma (OTHER), Treatment for Small Cell Lung Cancer (OTHER).
Who is sponsoring clinical trial NCT04452292?
This trial is sponsored by Charles Kunos, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04452292 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large Cell Neuroendocrine Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04452292's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
RECRUITING · Phase 1
-
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI